

**Registered Number 06447912**

**INTERNATIONAL HEALTH TECHNOLOGY LTD**

**Abbreviated Accounts**

**31 December 2012**

## Abbreviated Balance Sheet as at 31 December 2012

	Notes	2012	2011
		£	£
<b>Called up share capital not paid</b>		-	-
<b>Fixed assets</b>			
Intangible assets		-	-
Tangible assets	2	128,145	106,669
		<u>128,145</u>	<u>106,669</u>
<b>Current assets</b>			
Stocks		4,965	-
Debtors		244,042	580,754
Cash at bank and in hand		228,079	548,705
		<u>477,086</u>	<u>1,129,459</u>
<b>Creditors: amounts falling due within one year</b>		(293,755)	(1,105,315)
<b>Net current assets (liabilities)</b>		<u>183,331</u>	<u>24,144</u>
<b>Total assets less current liabilities</b>		<u>311,476</u>	<u>130,813</u>
<b>Creditors: amounts falling due after more than one year</b>		(116,667)	-
<b>Total net assets (liabilities)</b>		<u>194,809</u>	<u>130,813</u>
<b>Capital and reserves</b>			
Called up share capital	3	219	197
Share premium account		990,403	765,925
Profit and loss account		(795,813)	(635,309)
<b>Shareholders' funds</b>		<u>194,809</u>	<u>130,813</u>

- For the year ending 31 December 2012 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.
- The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
- These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

Approved by the Board on 29 October 2013

And signed on their behalf by:

**Troels Jordansen, Director**

**Notes to the Abbreviated Accounts for the period ended 31 December 2012****1 Accounting Policies****Basis of measurement and preparation of accounts**

The accounts have been prepared under the historical cost convention and in accordance with the Financial Reporting Standard for Smaller Entities effective April 2008.

**Turnover policy**

Turnover represents the total invoice value, excluding value added tax, of sales made during the year and derives from the provision of goods falling within the company's ordinary activities.

**Tangible assets depreciation policy**

Depreciation is provided at rates calculated to write off the cost less residual value of each asset over its expected useful life, as follows:

Office equipment - 10 - 25% straight line

**Other accounting policies****Research and Development**

Research expenditure is written off to the profit and loss account in the year in which it is incurred.

**Stock**

Stock is valued at the lower of cost and net realisable value.

**Deferred taxation**

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more, or a right to pay less or to receive more, tax.

Deferred tax assets are recognised only to the extent that the directors consider that it is more likely than not that there will be suitable taxable profits from which the future reversal of the underlying timing differences can be deducted.

**Foreign currencies**

Monetary assets and liabilities denominated in foreign currencies are translated into sterling at rates of exchange prevailing at the accounting date. transactions in foreign currencies are recorded at the date of the transactions. All differences are taken to the Profit and Loss account.

**Going Concern**

The accounts have been prepared on the going concern basis. The company is in a period of development and promotion of newly developed medical technologies and therefore current costs exceed income. The company relies on the continued financial support of the actual and potential shareholders, who intend to continue their support for the foreseeable future.

**2 Tangible fixed assets**

	£
<b>Cost</b>	
At 1 January 2012	122,419
Additions	59,363
Disposals	(14,347)
Revaluations	-
Transfers	-
At 31 December 2012	<u>167,435</u>
<b>Depreciation</b>	
At 1 January 2012	15,750
Charge for the year	28,378
On disposals	(4,838)
At 31 December 2012	<u>39,290</u>
<b>Net book values</b>	
At 31 December 2012	<u>128,145</u>
At 31 December 2011	<u>106,669</u>

### 3 Called Up Share Capital

Allotted, called up and fully paid:

	2012	2011
	£	£
21,900 Ordinary shares of £0.01 each (19,700 shares for 2011)	219	197

During the period, 2245 shares have been allotted with consideration totalling £224,500 thereby resulting in a share premium of £224,477.55.

#### Share Options

As at 31 December 2011, there were 290 options over 1p ordinary shares that were outstanding. The exercise period was 17/12/2008 - 17/12/2015 at a price per share of £83.68.

In the year ended 31 December 2011 the following additional share options were added:

10 options over 1p shares with an exercise period from 25/05/2012 - 25/09/2016 at a price per share of £84.39

On 7 October 2011, Gordon Wishart, a director of the company, was granted 150 options in consideration of the sum of £1.00. The options have an exercise period of 07/10/11 - 07/10/18 at a price per share of £20.00

On 7 October 2011, Illum Jordansen Holdings Limited, a company controlled by the director, Troels Jordansen, was granted 560 options in consideration of the sum of £1.00. The options have an exercise period of 07/10/11 - 07/10/18 at a price per share of £20.00.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.

